TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03083717

Intervention type: DIAGNOSTIC_TEST
Intervention: Collection of breath samples, followed by analysis of exhaled breath using nanomaterial-based sensors (NaNose)
Description: 2-3 liters of breath sample will be collected in chemically inert Mylar bags. The breath samples will then be immediately transferred from the Mylar bags to Tenax sorbent tubes using a dedicated pump. Tubes will be sealed and kept in 4˚C until NA-NOSE analysis.
Study: NCT02042066

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Omnispec model Vascuspec
Description: Energy Density: 0.09 - 0.1 mJ/mm2 Extracorporeal Shockwave Therapy
Study: NCT03893292

Intervention type: PROCEDURE
Intervention: Total knee replacement
Description: Patients will undergo total knee replacement surgery.

Intervention type: DEVICE
Intervention: COOLIEF
Description: The superior lateral genicular nerve, superior medial genicular nerve, and inferior medial geniculate nerve will be ablated.
Study: NCT00469079

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine gum and lozenge
Description: Nicotine replacement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Taboka
Description: smokeless tobacco product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Camel Snus
Description: smokeless tobacco product
Study: NCT03389243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metamizol
Description: in group M patients will receive pre-emptive analgesia using intravenous infusion of metamizol in a single dose of 1,25 gram

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metamizol
Description: in group M patients will receive pre-emptive analgesia using intravenous infusion of metamizol in a single dose of 1,25 gram

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol
Description: in group P patients will receive pre-emptive analgesia using intravenous infusion of metamizol in a single dose of 1,25 gram
Study: NCT01063907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-2478
Description: Administered Days 1, 4, 8 and 11 of a 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-2478
Description: Administered Days 1, 4, 8 and 11 of a 21 day cycle
Study: NCT01900340

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: IV saline infusion and intraduodenal administration of nutrients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exendin(9-39) plus ID nutrient
Description: Exendin(9-39) as intravenous infusion plus intraduodenal nutrient administration
Study: NCT03122015

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic clown distraction
Description: The presence of the therapeutic clown, which can adapt his interventions of distraction to the state of health of the patient and the culture of the child, is a multimodal and multi sensorial distraction intervention and can have an impact on health status, procedures, family and multidisciplinary team members. The results of five studies evaluated the effects of distraction by the clown therapy demonstrate a decrease in pain and anxiety in children aged 2 to 17 years, as well as parental anxiety in painful procedures involving needles such as venipuncture.
Study: NCT00752297

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Preservative-free Saline
Description: Subjects will receive five 0.1 mL intramuscular injections at the Day 0 Treatment Visit: two in each corrugator and one in the procerus muscle. The total treatment dose (sum of the five injections) to be administered will be 0.5 mL of the placebo (preservative-free saline).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mentor Purified Toxin
Description: All subjects will receive five 0.1 mL intramuscular injections (two in each corrugator and one in the procerus muscle) at each Treatment Visit. The total treatment dose (sum of the five injections) to be administered will be 30 U of PurTox. Subjects will have many Treatment Visits throughout the course of the three-year study.
Study: NCT04293757

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rotational angiography
Description: Preprocedural imaging before ablation
Study: NCT01063907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-2478
Description: Administered Days 1, 4, 8 and 11 of a 21 day cycle
Study: NCT04290858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: Nitric Oxide (NO) will be delivered together with the standard of care for a period of 20-30 minutes 2 times per day for 14 consecutive days from time of enrollment. Targeted concentration will have a tidal oscillation between 100 and 300 ppm, in order to maintain an average inhaled concentration from 140 to 180 ppm. The gas will be delivered through a CPAP circuit ensuring an end-expiratory pressure between 2 and 10 cmH2O or trough a non-rebreathing mask without positive end expiratory pressure, depending on the clinical needs of the patient.
Study: NCT02728856

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen Spray SPF50 Z15-034(BAY987516)
Description: Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shampoo Control
Description: Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shampoo Control
Description: Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen Spray SPF50 Z15-038(BAY987516)
Description: Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.
Study: NCT03059966

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Microsurgery technique for root coverage
Description: Microsurgery technique for root coverage adapted for macrosurgery

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Microsurgery technique for root coverage associated to EMD
Description: Microsurgery technique for root coverage adapted for macrosurgery associated to Enamel Matrix Derivative
Study: NCT01063907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-2478
Description: Administered Days 1, 4, 8 and 11 of a 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-2478
Description: Administered Days 1, 4, 8 and 11 of a 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Administered on Days 1, 4, 8 and 11 of a 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Administered on Days 1, 4, 8 and 11 of a 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Administered on Days 1, 4, 8 and 11 of a 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Administered on Days 1, 4, 8 and 11 of a 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Administered on Days 1, 4, 8 and 11 of a 21 day cycle
Study: NCT00927472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Malathion gel 0.5%
Description: Malathion gel 0.5% applied to scalp for 30 minutes. May be repeated in 1 week if head lice are still present.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Permethrin 1% rinse
Description: Permethrin 1% shampooed into scalp for 10 minutes. May be repeated in 1 week if head lice are still present.
Study: NCT00038610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: 600 mg by mouth on days 1 - 14 for course 1, and 600 mg by mouth daily days 1-14 (or daily if tolerated with course 1) for courses 2, 4, 6, 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 300 mg/m\^2 by vein every 12 hours for 6 doses days 1, 2, 3 (total dose 1800 mg/m\^2) for courses 1, 3, 5, 7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50 mg/m\^2 by vein on day 4 after last dose of CTX for courses 1, 3, 5, 7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 2 mg by vein on day 4 and day 11 for courses 1, 3, 5, 7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg by vein or by mouth daily on days 1 - 4 and days 11 - 14 for courses 1, 3, 5, 7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 12 mg intrathecally (6 mg if via Ommaya reservoir) day 2 for courses 1, 3, 5, 7.~200 mg/m\^2 by vein over 2 hours followed by 800 mg/m\^2 over 22 hours on day 1 of courses 2, 4, 6, 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 100 mg intrathecally day 7 for courses 1, 3, 5, 7.~3 gm/m2 by vein over 2 hrs every 12 hrs for 4 doses on days 2 and 3 for courses 2, 4, 6, 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: 600 mg/m\^2 by vein daily for 24 hours for courses 1, 3, 5, 7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 10 mcg/kg/day after completion of chemotherapy until neutrophil recovery to 1 x 109/L or higher for all courses.
Study: NCT03655002

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cytokine-based Biologic Agent IRX-2
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT04559529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) 500 mg
Description: The levetiracetam pill will look just like the placebo pill.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) 500 mg
Description: The levetiracetam pill will look just like the placebo pill.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo pill will look just like the levetiracetam pill, but does not contain any levetiracetam.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo pill will look just like the levetiracetam pill, but does not contain any levetiracetam.
Study: NCT02967380

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Description: Undergo DCE-MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobenate Dimeglumine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Gadopentetate Dimeglumine
Description: Given IV
Study: NCT02723487

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.125%
Description: Patients will receive bilateral Transversus Abdominis Plane Block guided by ultrasound device using bupivacaine (Marcaine, 0.125%), 0.5 ml/kg on each side.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.25%
Description: Patients will receive bilateral Transversus Abdominis Plane Block guided by ultrasound device using bupivacaine (Marcaine, 0.25%), 0.5 ml/kg on each side.
Study: NCT01153776

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 64-slice CT angiography
Description: the sensitivity and specificity of 64-slice CT angiography for the detection of lesions at the ostia and proximal segments of the reimplanted coronary arteries
Study: NCT00548405

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alemtuzumab 12 mg
Description: Alemtuzumab 12 milligram (mg) per day intravenous (IV) infusion on 5 consecutive days at Month 0, followed by alemtuzumab 12 mg per day IV infusion on 3 consecutive days at Month 12.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alemtuzumab 24 mg
Description: Alemtuzumab 24 mg per day IV infusion on 5 consecutive days at Month 0, followed by alemtuzumab 24 mg per day IV infusion on 3 consecutive days at Month 12.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Interferon beta-1a
Description: Interferon beta-1a 44 microgram (mcg) subcutaneously 3-times weekly for 24 months. Dose adjustment was done as per Investigator's discretion.
Study: NCT03462901

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous intramedullary fixation of displaced midshaft clavicular fractures .
Description: A group of 15 patients admitted to Assiut university with midshaft clavicular fractures treated by operative fixation of the fracture by single elastic rod through medial approach under image intensifier
Study: NCT00268580

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asthma Care Pathway
Description: Asthma care provided using standardized asthma care pathway
Study: NCT04607278

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Oral probiotic supplementation was provided by iHealth; Cromwell, USA. Each sachet included a 1×1010 CFUs dose of four viable microbial cell preparation strains: there are two strains of lactobacillus genus (Lactobacillus acidophillus L1 (2.9×109) and Lactobacillus rhamnosus liobif (2.9×109)), Bifidobacterium longum (2.9×109) and Saccharomyces boulardii (1.3×109). Each participant took a total daily dose of 4×1010 CFUs.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Prebiotic
Description: The prebiotic was made up of inulin from the chicory plant and provided by the Fibrelle (Belgium) company. Five grams packs were given to the participants in boxes. Each participant was requested to take a total daily 10 g dose.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: It was composed of maltodextrin, and provided by the manufacturer Fibrelle; (Belgium). The prescription was similar to probiotics or prebiotics groups.
Study: NCT02004639

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Masticators sparing techniques

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: electro-acupunture treatment
Description: electro-acupunture treatment and sham-EA

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: electro-acupunture treatment
Description: electro-acupunture treatment and sham-EA
Study: NCT04506762

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regional analgesia
Description: Insertion of bilateral ESP catheters
Study: NCT00911378

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pressure support ventilation
Description: These patients are weaned by gradual reduction of pressure support and extubated when they tolerate a pressure support of 7 cm of water for one hour.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spontaneous breathing trials
Description: These patients are weaned by giving a T piece trial with 8 cm of water pressure support and extubated when they tolerate it for one hour.
Study: NCT00005646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 150 mg/sq m IV over 3 hours weekly for 6 weeks per cycle
Study: NCT02217527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active JNJ Drug
Description: 200 mg/day (100 mg b.i.d.) of Active JNJ Drug will be used for one week while attempting to briefly quit smoking on Mon-Fri of that week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active JNJ Drug
Description: 200 mg/day (100 mg b.i.d.) of Active JNJ Drug will be used for one week while attempting to briefly quit smoking on Mon-Fri of that week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo pill
Description: Placebo pill will be taken daily to assess ability to briefly quit smoking on Mon-Fri for one week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo pill
Description: Placebo pill will be taken daily to assess ability to briefly quit smoking on Mon-Fri for one week.
Study: NCT00002642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 50 mg/m2, IV Days 1 and 8, two 28 day cycles prior to surgery and two 28 day cycles after surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 50 mg/m2, IV Days 1-5, two 28 day cycles prior to surgery and two 28 day cycles after surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: surgery some time between weeks 9 and 12
Study: NCT02333032

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inclined treadmill training
Study: NCT03101345

Intervention type: OTHER
Group type: OTHER
Intervention: Peptamen® 1.5 vanilla
Description: Administration orally
Study: NCT00088855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT00002642

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET cobalt-60 gamma ray therapy
Description: 180 cGy per day, Days 1-5, weekly for 5 weeks
Study: NCT01433276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperosmolar sodium lactate
Description: 1st loading : Upto 2 liters of Ringer's lactate, followed by Totilac which was given 5 mL/kgBW/15 minutes, followed by maintenance 2 mL/kgBW/hour for 3 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's lactate
Description: 1st loading : Upto 2 litres of Ringer's lactate, followed by 5 mL/kgBW/15 minutes,followed by maintenance : 2 mL/kgBW/hour for 3 hours
Study: NCT02621840

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mandatory On-Site Pre-Admission Testing
Study: NCT03389243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol
Description: in group P patients will receive pre-emptive analgesia using intravenous infusion of metamizol in a single dose of 1,25 gram
Study: NCT04967040

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: medial plantar artery flap
Description: Medial plantar artery flap is a fasciocutaneous island flap raised from the non-weightbearing instep of the plantar foot. The dominant vascular pedicle of the flap consists of the medial plantar artery and venae comitantes

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Distally based sural artery flap
Description: Distally based sural artery flap is a fascio-cutaneous island flap taken from the posterior aspect of the middle third of the leg and fed by the lower peroneal septo-cutaneous perforators in reverse fashion. Its vascular basis is the close association between the median superficial sural artery and peroneal artery perforators
Study: NCT00881543

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dipeptidyl Peptidase IV inhibitors
Description: Dosage 100 mg each day, once a day, 2 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dipeptidyl Peptidase IV inhibitors
Description: Dosage 100 mg each day, once a day, 2 months
Study: NCT02057328

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TELMISARTAN
Description: Patients of the group of telmisartan will take 40 mg of telmisartan daily in the morning. At the end of the first month of treatment, patients classified in the normal BP range based on the results of ABPM will continue on the same medication scheme. Patients still classified in the stage I hypertensive range will receive 80 mg of telmisartan daily in the morning. At the end of the 6th month from the beginning of the study patients classified in the normal BP range will continue on the same medication scheme. For patients still classified in the stage I hypertensive range12,5 mg of hydrochlorothiazide will be added. The end of the 12-month period from the beginning of the study indicates the completion of the project.
Study: NCT01604902

Intervention type: OTHER
Intervention: 4 mm punch biopsies
Description: 4 mm punch-biopsies from lesional and non-lesional psoriatic skin at day 0 and up to four times after treatment at the following days: 4, 14, 28 or 84.
Study: NCT03389243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol and metamizole
Description: in group PM patients will receive pre-emptive analgesia using intravenous infusion of metamizol in a single dose of 1,25 gram and paracetamol in a dose of 1 gram
Study: NCT02057328

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NEBIVOLOL
Description: Patients will take 5 mg of nebivolol daily in the morning. At the end of the first month of treatment, patients classified in the normal BP range based on the results of ABPM will continue on the same medication scheme. Patients classified in the stage I hypertensive range the nebivolol group will receive 10 mg of nebivolol daily in the morning. At the end of the 6th month from the beginning of the study patients classified in the normal BP range based on the results of ABPM will continue on the same medication scheme. For patients classified in the stage I hypertensive range 12,5 mg of hydrochlorothiazide will be added. The end of the 12-month period from the beginning of the study indicates the completion of the project
Study: NCT02978313

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI
Description: Irinotecan+LV5FU2
Study: NCT00652262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: Patients received BAY 38-9456 10 mg for the first 4 weeks of the treatment period, and then went on to receive 10 mg or 20 mg for the following 8 weeks.
Study: NCT03225521

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HeartSteps: A just-in-time adaptive intervention for increasing physical activity amongst sedentary adults.
Description: HeartSteps is an Android-based mHealth intervention that contains two main intervention components: contextually-tailored suggestions for activity and planning of the next day's activity. Activity suggestions provide individuals with actionable suggestions for how they can be active in their current context. Delivered suggestions are tailored based on time of day, user's location, day of the week (weekend/weekday), and weather. HeartSteps can deliver a user activity suggestions up to five times a day. Evening planning asks users to create or choose a plan of how they will be active on the following day. Planning can be delivered once a day, in the evening.
Study: NCT01969162

Intervention type: PROCEDURE
Intervention: Tear Sample Collection
Description: Tear sample collection as per protocol. No investigational drug is administered in this study.
Study: NCT02169947

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight loss core
Description: The weight loss core is a culturally adapted version of the Diabetes Prevention Program core 16 week session program.
Study: NCT01227824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572 (dolutegravir)
Description: GSK1349572 50 mg taken once daily with or without food